Hemostatics is developing a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling haemorrhagic conditions.
Thanks to an innovative mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is aiming to address a number of significant unmet medical needs in trauma, surgery, ICH, PPH, GI bleeding and in several bleeding disorders (Rare Diseases).
Company Details
- Employees
- 10
- Founded
- -
- Address
- Parc Científic De Barcelona, C. Baldiri Reixac,4-12,spain
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://hemostatics.com/
- Keywords
- healthcare, haemorrhage, ICH, Trauma, Drug Discovery, pharma, Heavy menstrual bleeding, Post-partum hemorrhage, Osler-Weber-Rendu syndrome, Hereditary cerebral hemorrhage with amyloidosis, Gastrointestinal bleeding, Accidents, Military Battlefield, Bleeding, Drug Development.
- HQ
- Barcelona
Hemostatics Questions
Hemostatics's website is https://hemostatics.com/
Hemostatics's LinkedIn profile is https://es.linkedin.com/company/hemostatics
Hemostatics has
10 employees.
View email and phone details for 10
employees at Hemostatics.
Hemostatics's industry is
Pharmaceutical Manufacturing
Hemostatics's top competitors are
Kennek,
Biofabri,
Nanobots Therapeutics,
Inbrain Neuroelectronics,
Wildgrace,
Fecundis Lab,
Leanbio S.l.,
Parc Científic De Barcelona,
Healthtech180,
Exostatics Pharmaceuticals.
Hemostatics's categories are Pharmaceutical Manufacturing
Hemostatics's founding year is 2020
